Star Metro - Chronic drug shortages frustrate EU pharmacists, patients

Like other EU nations, Belgium has increasingly experienced medicine shortages that vex pharmacists, exasperate patients and risk overloading public health services.

"There are often several dozen medications that are in short supply simultaneously, which makes our lives very difficult," said Didier Ronsyn, a Brussels pharmacist.

An EU audit last month found shortages were a "chronic headache" across the bloc.

Its 27 states reported running critically short of 136 drugs, including antibiotics and medicines used to treat heart attacks, between 2022 and 2024, the European Court of Auditors (ECA) said.

Belgium reported the most cases, with more than a dozen critical instances -- meaning no alternatives are available -- notified to the European Medicines Agency (EMA) in 2024 only.

The cause partially lies in supply chain snags and Europe's over-reliance on Asia for key drug components, the ECA said.

Cheaper prices mean that Asian producers now supply the EU with 70 percent of the active pharmaceutical ingredients it needs, according to a study cited in the ECA report.

The dependency is particularly acute for painkillers, like paracetamol or ibuprofen, and drugs that ran critically low in recent years, including some antibiotics and salbutamol, an asthma drug sold under the brand name Ventolin.

Yet, EU internal market inefficiencies are also to blame.

- 'Colossal workload' -

Drug prices differ within the bloc as national authorities negotiate individually with producers, explained Olivier Delaere, CEO of Febelco, a wholesale distributor that serves about 40 percent of Belgian pharmacies.

As a consequence, manufacturers tend to deliver more to countries that pay more, and just enough to those who drove a harder bargain -- to avoid drugs being re-exported for profit, he said.

Additionally, the ECA said that most medicines are still authorised at national level and packages differ significantly among countries, which makes internal EU trade "more costly and complex".

This causes so-called "local shortages", when a product is not available in one EU country but can be found just across the border in another member state, said Delaere of Febelco.

"It's a growing problem," he said, as a massive automated dispenser stacked with medicine boxes filled green baskets -- each corresponding to a pharmacist's order -- on a conveyor belt in the warehouse behind him.

Some 70 percent of the about one million client calls the firm receives a year "are focused solely on medicine shortages", Delaere said. "It is an absolutely colossal workload and energy drain."

- 'Complicated', for now -

In 2024, EU pharmacists spent on average 11 hours per week managing shortages, according to PGEU, a pharmacists' trade group.

Ronsyn said he often spends an hour a day "making phone calls, checking information, sending patients away, or calling them back to tell them their medication has arrived or in certain cases, that it hasn't" -- something that did not happen in the past.

"It's also tough for the patient, who might panic a little when they don't get their medication on time," he said.

Brussels has been scrambling to find solutions.

In March, the European Commission proposed a "critical medicines act" aimed at boosting manufacturing in the EU by providing incentives and urging member states to move away from price as the key criterion for awarding procurement contracts.

It was followed in July by a "stockpiling strategy" to coordinate stocks and ensure medicines and other goods are available in case of crisis.

A commission spokeswoman said Brussels was confident that these and other recently introduced proposals "will make a substantial difference" and "significantly help tackling the problem".

The bills are currently being negotiated with the European Parliament and member states, a sometimes lengthy process.

"They are trying to find solutions, but it is always very slow," said Ronsyn, whose pharmacy overlooks the commission offices. "We will probably get there someday, but for now it's complicated."

P.Lefebvre--SMC